Nastilox (Clopidogrel)

Clopidogrel, the active ingredient in Nastilox, is an antiplatelet agent presented as an oral formulation for oral use. It is employed to reduce the risk of atherothrombotic events in patients with prior myocardial infarction, stroke, peripheral arterial disease, or after coronary interventions. GNH USA supplies Nastilox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clopidogrel acts on platelet aggregation pathways to lower the incidence of cardiovascular complications. - Prevention of atherothrombotic events in patients with a history of myocardial infarction, stroke, or established peripheral arterial disease: reduces risk of recurrent heart attack, stroke and vascular death. - Secondary prevention after acute coronary syndrome: lowers the likelihood of subsequent myocardial infarction and cardiovascular mortality. - Prevention of stent thrombosis following percutaneous coronary intervention: helps maintain vessel patency after stent placement.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Minor bleeding: easy bruising, gum bleeding or occasional nosebleeds. - Headache: mild to moderate intensity. - Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal hemorrhage, intracranial bleeding or hematuria. - Thrombotic thrombocytopenic purpura (TTP): a rare blood disorder with low platelet count. - Allergic reactions: rash, itching, swelling or anaphylaxis. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating therapy, clinicians should assess individual bleeding risk and review concomitant medications. - Assess bleeding risk: evaluate history of ulcers, hemorrhagic disorders or recent surgery. - Monitor platelet function: periodic laboratory testing may be warranted in high‑risk patients. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Pregnancy and lactation: use only if potential benefit outweighs potential risk to fetus or infant. - Discontinue before surgery: stop clopidogrel as advised by the operating physician to reduce intra‑operative bleeding. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Clopidogrel interacts with several drug classes that can alter its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., fluconazole, voriconazole, omeprazole): may reduce conversion to the active metabolite and diminish efficacy. - Concurrent use of anticoagulants (e.g., warfarin, heparin) or other antiplatelet agents (e.g., aspirin, ticagrelor): markedly increases bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive effect on gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may enhance bleeding tendency. - Proton pump inhibitors (excluding pantoprazole): potential reduction in antiplatelet activity. - Statins metabolized by CYP3A4 (e.g., atorvastatin): may increase plasma concentrations of clopidogrel's active metabolite.